High-dose cyclophosphamide (NSC-26271) therapy in childhood acute leukemia

Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.

Leukemia·2005

A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial.

Leukemia·2001

Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.

Leukemia·2000

Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2000

Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821.

Blood·1999

A survey of pediatric malignancy in West Virginia.

The West Virginia medical journal·1998

Urinary excretion of polyamines by patients with advanced malignancy.

Cancer chemotherapy reports·1975

Chemotherapy of transplanted adenocarcinomas of the colon in mice.

Cancer chemotherapy reports·1975

Tissue disposition of 3H-actinomycin D (NSC-3053) in the rat, monkey, and dog.

Cancer chemotherapy reports·1975

Toxicology studies with cytembena (NSC-104801), an antineoplastic agent with a multispecies nephrotoxic effect.

Cancer chemotherapy reports·1975

Phase I study of corynebacterium parvum in patients with solid tumors.

Cancer chemotherapy reports·1975

Combination chemotherapy for acute nonlymphoblastic leukemia in adults.

Cancer chemotherapy reports·1975

Functional Brain Network Alterations Linked to Cancer-Related Cognitive Impairment in Breast Cancer Patients.

The oncologist·2026

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.

Oncoimmunology·2026

Intravesical gemcitabine versus Bacillus Calmette-Guérin (BCG) for intermediate-/high-risk non-muscle-invasive bladder cancer during the BCG shortage: Safety, efficacy, and health-economic context.

Investigative and clinical urology·2026

Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma.

Korean journal of radiology·2026

Cemiplimab in cutaneous squamous cell carcinoma: a longer follow-up study focusing on the late toxicities.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026

Not all anti-CD38 antibodies are created equal: The epitope of felzartamab is partially DTT-resistant.

Transfusion medicine (Oxford, England)·2026

Related Experiment Videos

High-dose cyclophosphamide (NSC-26271) therapy in childhood acute leukemia

Related Concept Videos

Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.

A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial.

Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.

Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.

Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821.

A survey of pediatric malignancy in West Virginia.

Urinary excretion of polyamines by patients with advanced malignancy.

Chemotherapy of transplanted adenocarcinomas of the colon in mice.

Tissue disposition of 3H-actinomycin D (NSC-3053) in the rat, monkey, and dog.

Toxicology studies with cytembena (NSC-104801), an antineoplastic agent with a multispecies nephrotoxic effect.

Phase I study of corynebacterium parvum in patients with solid tumors.

Combination chemotherapy for acute nonlymphoblastic leukemia in adults.

Functional Brain Network Alterations Linked to Cancer-Related Cognitive Impairment in Breast Cancer Patients.

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.

Intravesical gemcitabine versus Bacillus Calmette-Guérin (BCG) for intermediate-/high-risk non-muscle-invasive bladder cancer during the BCG shortage: Safety, efficacy, and health-economic context.

Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma.

Cemiplimab in cutaneous squamous cell carcinoma: a longer follow-up study focusing on the late toxicities.

Not all anti-CD38 antibodies are created equal: The epitope of felzartamab is partially DTT-resistant.

Related Experiment Videos

High-dose cyclophosphamide (NSC-26271) therapy in childhood acute leukemia

Related Concept Videos

Related Articles